These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 16351633

  • 1. Childhood acute lymphoblastic leukaemia and relapse.
    Gaynon PS.
    Br J Haematol; 2005 Dec; 131(5):579-87. PubMed ID: 16351633
    [Abstract] [Full Text] [Related]

  • 2. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
    You Y, Li QB, Chen ZC, Li WM, Xia LH, Zhou H, Zou P.
    Chin Med J (Engl); 2008 Sep 20; 121(18):1770-4. PubMed ID: 19080355
    [Abstract] [Full Text] [Related]

  • 3. Three cases of renal relapse after allogeneic hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia.
    Huck K, Laws HJ, Meisel R, Traeger A, Bernbeck B, Schonberger S, Stackelberg VA, Pape H, Dilloo D.
    Haematologica; 2006 May 20; 91(5 Suppl):ECR07. PubMed ID: 16709515
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients].
    Jin FY, Zou DH, Wang GR, Xu Y, Feng SZ, Zhao YZ, Han MZ, Yan WW, Qiu LG.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Nov 20; 26(11):645-8. PubMed ID: 16620547
    [Abstract] [Full Text] [Related]

  • 6. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
    Giebel S, Krawczyk-Kulis M, Adamczyk-Cioch M, Jakubas B, Palynyczko G, Lewandowski K, Dmoszynska A, Skotnicki A, Nowak K, Holowiecki J, Polish Adult Leukemia Group.
    Ann Hematol; 2006 Oct 20; 85(10):717-22. PubMed ID: 16832677
    [Abstract] [Full Text] [Related]

  • 7. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
    Arellano ML, Langston A, Winton E, Flowers CR, Waller EK.
    Biol Blood Marrow Transplant; 2007 Jan 20; 13(1):116-23. PubMed ID: 17222760
    [Abstract] [Full Text] [Related]

  • 8. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
    Burkhardt B, Reiter A, Landmann E, Lang P, Lassay L, Dickerhoff R, Lakomek M, Henze G, von Stackelberg A.
    J Clin Oncol; 2009 Jul 10; 27(20):3363-9. PubMed ID: 19433688
    [Abstract] [Full Text] [Related]

  • 9. Optimal management of adults with ALL.
    Rowe JM.
    Br J Haematol; 2009 Feb 10; 144(4):468-83. PubMed ID: 19055668
    [Abstract] [Full Text] [Related]

  • 10. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
    Fouillard L, Labopin M, Gratwohl A, Gluckman E, Frassoni F, Beelen DW, Willemze R, Montserrat E, Blaise D, Atienza AI, Sierra J, Santos M, Gorin NC, Rocha V, Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Haematologica; 2008 Jun 10; 93(6):834-41. PubMed ID: 18469352
    [Abstract] [Full Text] [Related]

  • 11. Pathways through relapses and deaths of children with acute lymphoblastic leukemia: role of allogeneic stem-cell transplantation in Nordic data.
    Saarinen-Pihkala UM, Heilmann C, Winiarski J, Glomstein A, Abrahamsson J, Arvidson J, Békássy AN, Forestier E, Jonmundsson G, Schroeder H, Vettenranta K, Wesenberg F, Gustafsson G.
    J Clin Oncol; 2006 Dec 20; 24(36):5750-62. PubMed ID: 17179109
    [Abstract] [Full Text] [Related]

  • 12. Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria--a population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group.
    Reismüller B, Attarbaschi A, Peters C, Dworzak MN, Pötschger U, Urban C, Fink FM, Meister B, Schmitt K, Dieckmann K, Henze G, Haas OA, Gadner H, Mann G, Austrian Berlin-Frankfurt-Münster (BFM) Study Group.
    Br J Haematol; 2009 Feb 20; 144(4):559-70. PubMed ID: 19077160
    [Abstract] [Full Text] [Related]

  • 13. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr 20; 25(4):486-9. PubMed ID: 16613686
    [Abstract] [Full Text] [Related]

  • 14. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, Csinady E, Dworzak MN, Seidel M, Janousek D, Möricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA.
    J Clin Oncol; 2008 Jun 20; 26(18):3046-50. PubMed ID: 18565891
    [Abstract] [Full Text] [Related]

  • 15. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
    Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A, ALL-REZ BFM Study Group.
    J Clin Oncol; 2009 Jan 20; 27(3):377-84. PubMed ID: 19064980
    [Abstract] [Full Text] [Related]

  • 16. Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse.
    Pulsipher MA, Bader P, Klingebiel T, Cooper LJ.
    Biol Blood Marrow Transplant; 2009 Jan 20; 15(1 Suppl):62-71. PubMed ID: 19147081
    [Abstract] [Full Text] [Related]

  • 17. Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia study (JACLS) ALL F-protocol.
    Suzuki N, Yumura-Yagi K, Yoshida M, Hara J, Nishimura S, Kudoh T, Tawa A, Usami I, Tanizawa A, Hori H, Ito Y, Miyaji R, Oda M, Kato K, Hamamoto K, Osugi Y, Hashii Y, Nakahata T, Horibe K, Japan Association of Childhood Leukemia Study (JACLS).
    Pediatr Blood Cancer; 2010 Jan 20; 54(1):71-8. PubMed ID: 19813250
    [Abstract] [Full Text] [Related]

  • 18. Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia.
    Claviez A, Eckert C, Seeger K, Schrauder A, Schrappe M, Henze G, von Stackelberg A.
    Haematologica; 2006 Feb 20; 91(2):272-3. PubMed ID: 16461321
    [Abstract] [Full Text] [Related]

  • 19. Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study Group.
    Stanulla M, Cario G, Meissner B, Schrauder A, Möricke A, Riehm H, Schrappe M.
    Blood Cells Mol Dis; 2007 Feb 20; 39(2):160-3. PubMed ID: 17532236
    [Abstract] [Full Text] [Related]

  • 20. Allogeneic transplantation for childhood ALL.
    Mehta PA, Davies SM.
    Bone Marrow Transplant; 2008 Jan 20; 41(2):133-9. PubMed ID: 17994118
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.